Barclays raises Globus Medical stock price target to $106 on margin strength

Barclays raised its price target on Globus Medical (GMED) to $106 from $103, maintaining an Overweight rating, driven by the company's earnings beat, robust 7.4% underlying U.S. spine growth, and improving robot trends. This positive outlook is supported by GMED's strong fundamentals, including a 67% gross profit margin and expectations to exit the year with over 30% EBITDA margins, despite preliminary Q2 2025 base business revenue slightly missing consensus and a planned CEO transition. The new target is based on a 13.5x EV/EBITDA multiple on projected next-twelve-months EBITDA, signaling continued analyst confidence in the medical device firm's trajectory.

Analysis

Barclays has increased its price target for Globus Medical (GMED) to $106.00, maintaining an Overweight rating, which suggests significant upside from its current trading price of $57.78. This bullish stance is underpinned by a recent earnings beat, driven by strong 7.4% underlying U.S. spine growth, positive sales and margin contributions from the Nevro (NVRO) acquisition, and improving robotics trends. The company's fundamentals appear robust, with a 67% gross profit margin and 17.4% revenue growth over the last twelve months, and it is projected to exit the year with EBITDA margins exceeding 30%. However, this optimism is tempered by several key factors. While preliminary Q2 2025 revenue of $745 million surpassed consensus, the core base business revenue of $651 million fell short of the $664 million expectation, indicating that acquisition-related revenue is masking potential weakness in organic growth. Furthermore, the company is navigating a significant leadership transition, with a new President and CEO, Keith Pfeil, taking over in July 2025. This management uncertainty is a primary reason for Needham's Hold rating, creating a divergence in analyst sentiment despite Piper Sandler reiterating its Overweight rating.

Key Decisions for Investors

• Given the substantial gap between the current stock price and Barclays' $106 target, investors might consider the stock undervalued, but should be aware that this thesis relies on achieving synergies from the NVRO acquisition and sustained robotics momentum.
• It is critical to monitor the company's upcoming earnings reports for a stabilization and re-acceleration in the base business organic growth, as the recent miss in this area is a notable red flag.
• The pending CEO transition introduces execution risk; investors should closely watch for strategic shifts under the new leadership and assess their ability to manage the NVRO integration effectively before committing new capital.
• The valuation target is based on a forward EV/EBITDA multiple of 13.5x on H2 2026/H1 2027 estimates, so investors should stress-test the achievability of the underlying $1.03 billion EBITDA projection.